Vimarsana
Biggest News Aggregation in the World

Stephen Bardin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stephen Bardin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stephen Bardin Today - Breaking & Trending Today

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer - ATAI Life Sciences (NASDAQ:ATAI) - Vimarsana News

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer - ATAI Life Sciences (NASDAQ:ATAI)

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and

Atai Life Sciences Appoints Anne Johnson as Chief Financial Officer - Vimarsana News

Atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

NEW YORK and BERLIN, Feb. 06, 2024 -- atai Life Sciences  today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since...

atai Life Sciences to Participate in Upcoming June Investor Conferences - Vimarsana News

atai Life Sciences to Participate in Upcoming June Investor Conferences

NEW YORK and BERLIN, June 01, 2023(NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming June Investor

Atai Life Sciences to Participate in Upcoming June Investor Conferences - Vimarsana News

Atai Life Sciences to Participate in Upcoming June Investor Conferences

NEW YORK and BERLIN, June 01, 2023 -- atai Life Sciences  , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in... | June 1, 2023

Atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates - Vimarsana News

Atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed Phase 1 study, which suggest the... | May 11, 2023